Western Canadian Neuromuscular Conference Accepting Scientific Abstracts for Research Symposium
The 5th Western Canadian Neuromuscular Conference is being held in Calgary on September 27 – 29, 2024. The conference is designed for general neurologists, neuromuscular specialists, physical medicine and rehabilitation specialists, trainee physicians with interest in Neuromuscular Medicine and allied health members from the neuromuscular community.
The WCNMC provides updates on recent advances in the diagnosis and management of common nerve, muscle and motor neuron diseases, witha blend of short didactic presentations, interactive discussions, plenary sessions and question answer, and a research symposium.
The research symposium on Sunday September 29 will focus on focus on trainee-led basic science, translational, clinical, and qualitative research related to neuromuscular disease. We encourage anyone attending the event to submit an abstract for consideration!
Abstracts for the research symposium will be accepted until September 6, 2024. Please visit the WCNMC website for instructions on how to submit your abstract.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.